Specifically, when administering short-term insulin therapy in early T2DM, an underlying goal of the intervention is to ameliorate the reversible component of beta-cell dysfunction that exists early in the natural history of diabetes15. The gene discussed is INS; the disease is type 2 diabetes mellitus.